BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

NAMS upcoming catalysts

NewAmsterdam Pharma: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 3 readout(s) and 0 FDA event(s). Subscribe to NAMS (.ics).

Drugs: Obicetrapib

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2NewAmsterdam Pharma NAMSNCT06496243 Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) LevelsDyslipidemiasrecruiting69
2026-11 est.P3NewAmsterdam Pharma NAMSNCT05202509 Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular DiseaseAtherosclerotic Cardiovascular Diseaseactive not recruiting9541
2026-09 est.P2NewAmsterdam Pharma NAMSNCT06982508 Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy VolunteersAntioxidant Absorptionrecruiting100

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.